South Korean clinical-stage biotech company ABL Bio (KOSDAQ:298380) signed a global licensing deal with British pharmaceutical and biotechnology firm GlaxoSmithKline to develop neurodegenerative disease treatments using its Grabody-B blood-brain barrier shuttle platform.
The agreement includes an upfront and near-term payment of up to 77.1 million pounds, with total milestone payments potentially reaching 2.075 billion pounds, ABL Bio said Sunday.
GlaxoSmithKline will lead the development, manufacturing, and commercialization efforts, while ABL Bio will receive tiered royalties on future sales, the release said.
ABL Bio hit the daily trading limit on Monday, soaring 29.96% to 44,250 won following the deal on Sunday, according to Pulse News.
Shares of the company jumped over 17% in recent trade on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.